These trials showed clinically major pharmacokinetic interactions [seven] characterised by a reduce while in the clearance of the anticancer drug and that's why amplified exposure. The interpretation of subsequent phase II and III clinical trials was complex since it was not possible to administer precisely the same dose of chemotherapy in the pres